AMENDMENTS TO THE CLAIMS

1. - 7. (canceled)

8. (currently amended) A pharmaceutical composition for the ~~treatment or~~ prevention of disease conditions mediated by 5-HT_4 receptor activity, in a mammalian subject, which comprises a therapeutically effective amount of ~~a compound of Claim 1~~ a compound of the formula (I):



(I)

or the pharmaceutically acceptable salts thereof wherein

$\mathbf{R^1}$ is hydrogen, halo or C_{1-6} alkyl;

$\mathbf{R^2}$ and $\mathbf{R^3}$ are independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, mono- or di-(C_{1-5})alkyl amino, amino(C_{1-5})alkyl or hydroxy(C_{1-5})alkyl; or R^2 and R^3 taken together with the nitrogen atom to which they are attached may form substituted or non-substituted nitrogen-containing hetrocyclic;

$\mathbf{R^4}$ is hydrogen, halo, C_{1-8} acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C_{1-6})alkyl, or substituted or non-substituted heterocyclic;

$\mathbf{R^5}$ is hydrogen, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-8} acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C_{1-6})alkyl, or substituted or non-substituted heterocyclic;

$\mathbf{R^6}$ is hydrogen, C_{1-6} alkyl or C_{1-6} alkoxy (C_{1-6})alkyl;

X is NR^9 wherein R^9 is hydrogen or C_{1-6} alkyl; and

Y is $(CR^7R^8)_n$ wherein R^7 and R^8 are independently hydrogen or C_{1-6} alkyl, and n is an integer from 0 to 5.;

and a pharmaceutically acceptable carrier.

9. (currently amended) A pharmaceutical composition for the ~~treatment or~~ prevention of gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, upper gut motility disorder, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome, constipation, dyspepsia, esophagitis, gastroesophageral disease, ~~aausea~~ nausea, central nervous system disease, alzheimers disease, cognitive disorder, emesis, migraine, neurological disease, pain, ischaemic stroke, anxiety or cardiovascular disorder, which comprises a therapeutically effective amount of ~~a compound of Claim 1~~ a compound of the formula (I):



(I)

or the pharmaceutically acceptable salts thereof wherein

R^1 is hydrogen, halo or C_{1-6} alkyl;

R^2 and **R^3** are independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, mono- or di-(C_{1-5})alkyl amino, amino(C_{1-5})alkyl or hydroxy(C_{1-5})alkyl; or R^2 and R^3 taken together with the nitrogen atom to which they are attached may form substituted or non-substituted nitrogen-containing hetrocyclic;

R^4 is hydrogen, halo, C_{1-8} acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C_{1-6})alkyl, or substituted or non-substituted heterocyclic;

R^5 is hydrogen, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-8} acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C_{1-6})alkyl; or substituted or non-substituted heterocyclic;

R^6 is hydrogen, C_{1-6} alkyl or C_{1-6} alkoxy (C_{1-6})alkyl;

X is NR^9 wherein R^9 is hydrogen or C_{1-6} alkyl; and

Y is $(CR^7R^8)_n$ wherein R^7 and R^8 are independently hydrogen or C_{1-6} alkyl, and n is an integer from 0 to 5.;

and a pharmaceutically acceptable carrier.

10. (currently amended) A method for the ~~treatment or~~ prevention of disease conditions mediated by 5-HT_4 receptor activity, in a mammalian subject, which comprises administering to said subject a therapeutically effective amount of ~~a compound according to Claim 1~~ a compound of the formula (I):



(I)

or the pharmaceutically acceptable salts thereof wherein

R^1 is hydrogen, halo or C_{1-6} alkyl;

R^2 and **R^3** are independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, mono- or di-(C_{1-5})alkyl amino, amino(C_{1-5})alkyl or hydroxy(C_{1-5})alkyl; or R^2 and R^3 taken together with the nitrogen atom to which they are attached may form substituted or non-substituted nitrogen-containing hetrocyclic;

R^4 is hydrogen, halo, C_{1-8} acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C_{1-6})alkyl, or substituted or non-substituted heterocyclic;

R^5 is hydrogen, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-8} acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C_{1-6})alkyl, or substituted or non-substituted heterocyclic;

R^6 is hydrogen, C_{1-6} alkyl or C_{1-6} alkoxy (C_{1-6})alkyl;

X is NR^9 wherein R^9 is hydrogen or C_{1-6} alkyl; and

Y is $(CR^7R^8)_n$ wherein R^7 and R^8 are independently hydrogen or C_{1-6} alkyl, and n is an integer from 0 to 5.

11. (currently amended) A method for the ~~treatment or~~ prevention of gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, upper gut motility disorder, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome, constipation, dyspepsia, esophagitis, gastroesophageral disease, ~~aausea~~ nausea, central nervous system disease, alzheimers disease, cognitive disorder, emesis, migraine, neurological disease, pain, ischaemic stroke, anxiety or cardiovascular disorder, which comprises administering to said subject a therapeutically effective amount of ~~a compound according to Claim 1~~ a compound of the formula (I):



(I)

or the pharmaceutically acceptable salts thereof wherein

R^1 is hydrogen, halo or C_{1-6} alkyl;

R^2 and R^3 are independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, mono- or di-(C_{1-5})alkyl amino, amino(C_{1-5})alkyl or hydroxy(C_{1-5})alkyl; or R^2 and R^3 taken together with the nitrogen atom to which they are attached may form substituted or non-substituted nitrogen-containing hetrocyclic;

R^4 is hydrogen, halo, C_{1-8} acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C_{1-6})alkyl, or substituted or non-substituted heterocyclic;

R^5 is hydrogen, halo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-8} acyl, amino, amido, substituted or non-substituted aryl, substituted or non-substituted aryl(C_{1-6})alkyl, or substituted or non-substituted heterocyclic;

R^6 is hydrogen, C_{1-6} alkyl or C_{1-6} alkoxy (C_{1-6})alkyl;

X is NR^9 wherein R^9 is hydrogen or C_{1-6} alkyl; and

Y is $(CR^7R^8)_n$ wherein R^7 and R^8 are independently hydrogen or C_{1-6} alkyl, and n is an integer from 0 to 5.

12. – 13. (canceled)